AlphAIAlphAI — Financial news for AI agents
TradingViewMAY 163 min read$CGEN

Compugen Ltd expected to post a loss of 7 cents a share - Earnings Preview

Compugen Ltd is expected to report a loss of 7 cents per share. This earnings preview provides a brief outlook on the company's financial performance.

Original reporting
TradingView · Refinitiv
Published May 16, 2026, 2:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 16, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Compugen Ltd expected to post a loss of 7 cents a share - Earnings Preview — source image
Source · TradingView
Decision brief

The 30-second read

$CGENBearishHigh
01

Why it matters

The earnings forecast indicates challenges ahead, possibly due to R&D setbacks or market conditions.

02

Market read

High relevance for biotech investors; sector sentiment may be affected.

03

What to watch

Potential positive catalysts such as upcoming product approvals or partnerships that could offset earnings concerns.

Relevance 6/10Timing: Immediate, as earnings release is imminent or has just occurred.

Background

Compugen Ltd operates in the biotech/life sciences sector, with recent developments including pipeline updates and strategic collaborations.

Company-level read

Ticker impact

$CGENBearishHigh confidence
Context

High relevance due to direct impact on company's financials and bearish sentiment.

Expected impact

Moderate decline expected in the near term, approximately 5-8% based on earnings disappointment.

Evidence & confidence

Earnings reports significantly influence stock price, and a predicted loss coupled with bearish sentiment supports a downward movement.

Market effects

Sector

Potential negative sentiment in the biotech/life sciences sector due to earnings outlook.

Regional

Limited, as company-specific news; regional effects minimal.

Global

Low, as it pertains to a single company's earnings.

Counterpoint

What could challenge this read

The company might have already priced in the expected loss, and actual results could be better than forecast, leading to a rebound.

Key entities

  • Company
    Compugen Ltd

    A biotech company focused on immunotherapy and cancer treatment.

Read at source← All news

Related articles

AUG 3
$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

prnewswire.com7 min
OCT 8
$RCLHigh

Jefferies upgrades Royal Caribbean stock rating on improved revenue outlook

Jefferies upgraded Royal Caribbean (RCL) to Buy with a $330 price target, citing improved occupancy and revenue per passenger. RCL trades at $282.32, with a P/E ratio of 17.66. Jefferies raised revenue estimates for Q3 2026 and FY 2027, projecting net yield growth and higher EBITDA. Despite lower EPS estimates, the firm increased valuation multiples. Other analysts also upgraded RCL, citing strategic developments and positive yield outlooks.

investing.com2 min
OCT 8
$NGNEHigh

JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

investing.com2 min
OCT 8
$BHVNMed

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven (BHVN) has entered a licensing agreement with Ono Pharma for its extracellular IgG degraders in Japan and select Asian regions. Biohaven will receive up to $100 million in payments, including $80 million upfront, and 20% royalties on net sales. The lead candidate, BHV-1300, is in Phase 3 trials for Graves' disease. Biohaven retains rights to the portfolio outside the licensed territory.

prnewswire.com2 min